On 28 August 2006, orphan designation (EU/3/06/394) was granted by the European Commission to Analytica International GmbH, Germany, for autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin for the treatment of follicular lymphoma.
The sponsorship was transferred to Analytica International Inc. - Outcomes Research and Pricing, Germany, in May 2011 and subsequently to Biovest Europe Limited, United Kingdom, in September 2011.
Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin
Treatment of follicular lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Biovest Europe Limited
70 Great Bridgewater St.
Manchester M1 5ES
Telephone: +44 845 497 8663
Telefax: +44 845 497 8888
Documents related to this orphan designation evaluation
EU/3/06/394: Public summary of positive opinion for orphan designation of autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin for the treatment of follicular lymphoma (PDF/124.28 KB)
First published: 02/04/2009
Last updated: 14/06/2012
EMEA/COMP/280125/2006 Rev. 3
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: